Oculoplastics

Teprotumumab shows promise in treating chronic-low clinical activity score thyroid eye disease

Teprotumumab can significantly improve proptosis in patients with chronic thyroid eye disease (TED) who have low levels of inflammation, according to new data presented at ENDO 2023. This is the first time positive results have been observed in patients with longstanding TED. The randomized, placebo-controlled trial enrolled patients who had...